Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride reduces hepatic glucose production and increases peripheral insulin sensitivity, while Sitagliptin blocks the DPP‑4 enzyme, raising levels of incretin hormones that stimulate insulin release and suppress glucagon. Together, they lower fasting and post‑prandial blood glucose, helping patients achieve target glycaemic control.

The dosage of Jansitin Duo is individualized by the prescribing clinician based on the patient’s renal function, glycaemic targets, and concomitant therapies. Physicians typically start with a low dose and titrate as needed, following local prescribing guidelines and monitoring blood glucose and safety parameters.

Safety of Jansitin Duo in pregnancy and lactation has not been established. Current guidance advises avoiding its use unless the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Jansitin Duo, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and assistance with import documentation.

Compared with metformin or sitagliptin monotherapy, Jansitin Duo offers dual mechanisms in a single tablet, potentially improving adherence and providing greater HbA1c reduction. It is generally more effective than either component alone but may carry a higher risk of combined side‑effects, requiring careful patient selection and monitoring.

Store Jansitin Duo at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the tablet container tightly closed and out of reach of children. Do not store in a refrigerator or freezer unless specifically instructed by the supplier.

Jansitin Duo is taken orally as a whole tablet, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed with a full glass of water and not crushed or chewed, unless a prescriber advises otherwise.

The most serious risks include lactic acidosis (especially in patients with renal impairment), acute pancreatitis, severe hypoglycaemia when combined with insulin or sulfonylureas, and rare allergic reactions such as rash or angio‑edema. Patients should be instructed to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, or signs of an allergic reaction.

Jansitin Duo is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease, heart failure, or uncontrolled heart rhythm disorders.